TY - JOUR T1 - Clinical experience with orphan drugs for rare metabolic diseases JO - Anales de Pediatría (English Edition) T2 - AU - Caso-González,Alicia AU - Núñez-Rodríguez,Jesica AU - Nebot-Villacampa,María-José AU - González-Pérez,Yared AU - Marín-Gorricho,Raquel AU - Leralta-González,Claudia AU - Obaldia-Alaña,Carmen SN - 23412879 M3 - 10.1016/j.anpede.2020.09.014 DO - 10.1016/j.anpede.2020.09.014 UR - https://www.analesdepediatria.org/en-clinical-experience-with-orphan-drugs-articulo-S234128792100209X AB - IntroductionInborn errors of metabolism are a highly heterogeneous group of orphan diseases. Diet therapy and enzyme and coenzyme replacement are the most frequently used treatment. There are few patients and published studies about inborn errors of metabolism. The main objective of this study was to describe the effectiveness of orphan drugs in inborn errors of metabolism in paediatric patients. Material and methodsRetrospective descriptive study of 24 months on patients diagnosed with inborn errors of metabolism during childhood and who attended the pharmacy clinic or Day-Care Unit of a 630-bed general hospital. ResultsThe study included 15 patients with a median age of 17.8 years and were treated with nine different drugs: sapropterin, sodium phenylbutyrate, miglustat, velaglucerase, sebelipase, idursulfase, 5-hydroxytryptophan, succinate, and riboflavin. Seven different inborn errors of metabolism were observed: phenylketonuria, defects of the urea cycle, Gaucher, Nieman-Pick, Hunter’s disease, along with acid lipase deficiency, and mitochondrial diseases. Orphan drugs used for the treatment of inborn errors of metabolism accounted for 1.3% of hospital drug costs. Some orphan drugs achieved asymptomatic patients, but others just produced a modest symptomatic improvement. Most patients showed good tolerance to the treatment. ConclusionsOrphan drugs used in inborn errors of metabolism had an easy to manage toxicity profile, with many disparities in effectiveness. These drugs have a high economic impact. The cost-effectiveness ratio for orphan drugs is a controversial issue due to their high cost and the inconclusive clinical evidence. ER -